文献速递眼底病与葡萄膜炎

口服二甲双胍通过调节肠-视网膜轴抑制脉络膜新生血管

Oral Metformin Inhibits Choroidal Neovascularization by Modulating the Gut-Retina Axis.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2023-01-01

本研究在小鼠激光诱导脉络膜新生血管(CNV)模型中,每日口服二甲双胍300 mg/kg或溶媒,评估CNV大小、视网膜色素上皮/脉络膜转录组及肠道菌群。结果显示二甲双胍减少CNV大小(P < 0.01)和Iba1+巨噬细胞/小胶质细胞浸润(P < 0.005),改变肠道菌群并增加粪便丁酸、琥珀酸和胆酸水平;在无菌小鼠中二甲双胍不抑制CNV,但用二甲双胍处理SPF小鼠的粪菌移植定植菌群耗竭小鼠后可抑制CNV。作者认为口服二甲双胍通过调节肠道菌群抑制CNV。

要点

  • 口服二甲双胍300 mg/kg减少激光诱导CNV大小(P < 0.01)及Iba1+巨噬细胞/小胶质细胞浸润(P < 0.005)。
  • 二甲双胍组鉴定出145个差异表达基因(P < 0.05),促血管生成基因Tie1、Pgf和Gata2下调。
  • 二甲双胍改变肠道菌群,增加双歧杆菌属和Akkermansia,粪便丁酸、琥珀酸和胆酸显著升高。

核心结论

  • 作者认为口服二甲双胍通过调节肠道菌群抑制CNV,即晚期新生血管性AMD的标志性病变。

研究设计与样本

  • 研究使用无特定病原体(SPF)雄性小鼠,每日口服灌胃二甲双胍300 mg/kg或溶媒。
  • 选择雄性小鼠以尽量减少性别特异性差异对激光诱导和二甲双胍反应的影响。
  • 采用异凝集素和Iba1免疫染色评估激光诱导CNV大小及巨噬细胞/小胶质细胞浸润。
  • 使用Illumina对RPE/脉络膜进行高通量RNA-seq,并用16S rRNA测序/鸟枪法宏基因组学分析粪便菌群组成/通路及微生物衍生代谢物(包括短链脂肪酸和胆汁酸)。
  • 在二甲双胍处理的无菌(GF)小鼠及接受二甲双胍处理SPF小鼠粪菌移植(FMT)的抗生素处理/GF小鼠中重复研究。

主要发现

  • 二甲双胍治疗减少CNV大小(P < 0.01)并减少Iba1+巨噬细胞/小胶质细胞浸润(P < 0.005)。
  • 二甲双胍组鉴定出145个差异表达基因(P < 0.05),促血管生成基因Tie1、Pgf和Gata2下调。
  • 二甲双胍改变肠道菌群,有利于双歧杆菌属和Akkermansia,粪便丁酸、琥珀酸和胆酸水平显著增加。
  • 二甲双胍在GF小鼠中不抑制CNV,但用二甲双胍来源FMT定植菌群耗竭小鼠可抑制CNV。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Emerging data indicate that metformin may prevent the development of age-related macular degeneration (AMD). Whereas the underlying mechanisms of metformin's anti-aging properties remain undetermined, one proposed avenue is the gut microbiome. Using the laser-induced choroidal neovascularization (CNV) model, we investigate the effects of oral metformin on CNV, retinal pigment epithelium (RPE)/choroid transcriptome, and gut microbiota. METHODS: Specific pathogen free (SPF) male mice were treated via daily oral gavage of metformin 300 mg/kg or vehicle. Male mice were selected to minimize sex-specific differences to laser induction and response to metformin. Laser-induced CNV size and macrophage/microglial infiltration were assessed by isolectin and Iba1 immunostaining. High-throughput RNA-seq of the RPE/choroid was performed using Illumina. Fecal pellets were analyzed for gut microbiota composition/pathways with 16S rRNA sequencing/shotgun metagenomics, as well as microbial-derived metabolites, including small-chain fatty acids and bile acids. Investigation was repeated in metformin-treated germ-free (GF) mice and antibiotic-treated/GF mice receiving fecal microbiota transplantation (FMT) from metformin-treated SPF mice. RESULTS: Metformin treatment reduced CNV size (P < 0.01) and decreased Iba1+ macrophage/microglial infiltration (P < 0.005). One hundred forty-five differentially expressed genes were identified in the metformin-treated group (P < 0.05) with a downregulation in pro-angiogenic genes Tie1, Pgf, and Gata2. Furthermore, metformin altered the gut microbiome in favor of Bifidobacterium and Akkermansia, with a significant increase in fecal levels of butyrate, succinate, and cholic acid. Metformin did not suppress CNV in GF mice but colonization of microbiome-depleted mice with metformin-derived FMT suppressed CNV. CONCLUSIONS: These data suggest that oral metformin suppresses CNV, the hallmark lesion of advanced neovascular AMD, via gut microbiome modulation.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Zhang JY, Xiao J, Xie B, et al. Oral Metformin Inhibits Choroidal Neovascularization by Modulating the Gut-Retina Axis. Invest Ophthalmol Vis Sci. 2023. PMID: 38108689. doi:10.1167/iovs.64.15.21

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。